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animals as well as present advantages and disadvantages 
of these models.
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Introduction
Heart failure is amongst the leading causes of death and dis-
ability worldwide and can be defined as the end result of any 
abnormality in cardiac structure and function that leads to 
impaired ventricular filling or ejection [1].
Heart failure can be divided into two distinct entities, 
i.e. heart failure with reduced ejection fraction (HFrEF) 
and heart failure with preserved ejection fraction (HFpEF). 
HFrEF is related to systolic dysfunction and characterised 
by the inability of the myocardium to contract and eject 
enough blood. In turn, HFpEF is associated with diastolic 
dysfunction while systolic function is normal or near-
normal (hence preserved ejection fraction) [1]. Moreover, 
HFpEF displays no cardiac dilation, yet is characterised by 
high filling pressures and lung congestion, dyspnoea and 
intolerance to effort. Due to these reasons, exercise testing 
plays an important role in the diagnosis of HFpEF.
Myocardial remodelling in HFpEF is characterised by 
abnormal diastolic left ventricular (LV) function result-
ing from conditions such as increased stiffness, abnormal 
ventricular-arterial interaction, increased vascular stiff-
ness, endothelial dysfunction, chronotropic incompetence, 
impaired relaxation and/or cardiovascular reserve function. 
Among these, the most important mechanisms underlying 
diastolic dysfunction are disturbed myocardial relaxation 
and/or altered passive properties of the ventricular wall. Its 
phenotype is frequently, but not necessarily always, associ-
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Abstract Heart failure with preserved ejection fraction 
(HFpEF) constitutes a clinical syndrome in which the di-
agnostic criteria of heart failure are not accompanied by 
gross disturbances of systolic function, as assessed by 
ejection fraction. In turn, under most circumstances, dia-
stolic function is impaired. Although it now represents 
over 50 % of all patients with heart failure, the mecha-
nisms of HFpEF remain understood, precluding effective 
therapy. Understanding the pathophysiology of HFpEF has 
been restricted by both limited access to human myocar-
dial biopsies and by the lack of animal models that fully 
mimic human pathology. Animal models are valuable re-
search tools to clarify subcellular and molecular mecha-
nisms under conditions where the comorbidities and other 
confounding factors can be precisely controlled. Although 
most of the heart failure animal models currently available 
represent heart failure with reduced ejection fraction, sev-
eral HFpEF animal models have been proposed. However, 
few of these fulfil all the features present in human disease. 
In this review we will provide an overview of the currently 
available models to study HFpEF from rodents to large 
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present all the haemodynamic characteristics of human 
HFpEF, and few have proven to be reliable for preclinical 
evaluation of potentially new therapeutic targets. In this 
review, we present an overview of the currently available 
animal models that are employed in the study of HFpEF, 
including rodent and large animal models, and discuss the 
strengths and weaknesses of these models.
Animal models of HFpEF
Currently, the limited availability of animal models of 
HFpEF has potentially represented a major limitation in 
conducting mechanistic studies and unravelling HFpEF 
pathophysiology [4]. This is not only due to the absence of 
clear criteria and cut-off values for the diagnosis of HFpEF 
in animals but also due to the fact that these experimental 
models are more challenging, expensive and time consum-
ing when compared to HFrEF. Therefore, the majority of 
heart failure animal models have been developed for HFrEF. 
However, animal models of diastolic dysfunction have also 
become more widely available and closely resemble the 
pathophysiological mechanisms underlying the disease [5]. 
The animal models currently available have attempted to 
reproduce the paramount factors typically documented to 
cause diastolic dysfunction and HFpEF, namely ageing, 
diabetes mellitus and hypertension. The animal models 
highlighted in this review were successfully established in 
rodents (Table 1), while others were developed in large ani-
mals (Table 2).
ated with increased interstitial fibrosis with LV concentric 
remodelling/hypertrophy and atrial enlargement (Fig. 1; 
[2]). These patients are generally older and mainly female 
and exhibit a large number of comorbidities, including 
diabetes mellitus (DM), hypertension, obesity and renal 
dysfunction [1]. HFpEF is thus an exemplar multifacto-
rial disease and patient heterogeneity is not restricted to the 
heart, but also involves comorbidities affecting the entire 
cardiovascular system.
HFpEF is a major and growing epidemiological clini-
cal problem worldwide, whose prevalence has strikingly 
grown due to increasing prevalence of risk factors in an 
ageing population [2]. In Europe and in the USA, HFpEF 
currently accounts for over 50 % of all heart failure cases. 
Despite being responsible for frequent hospitalisations, high 
consumption of resources and a prognosis as ominous as 
that of HFrEF [3], evidence-based therapeutic strategies 
are still lacking and its treatment remains largely empiri-
cal [2]. Indeed, large-scale trials with conventional HFrEF 
approaches have failed in HFpEF and there is an urgent 
need to better understand its underlying pathophysiologi-
cal mechanisms [2]. Thus, so far, treatment options are lim-
ited and mostly based on the treatment and relief of other 
comorbidities.
The development of effective therapeutic strategies 
for HFpEF is hampered by the lack of appropriate animal 
models. Only a few animal models of HFpEF have been 
proposed, reflecting the difficulties in replicating the clini-
cal features of HFpEF in animals. Most of them consist of 
cardiac pressure-overload models that further develop LV 
concentric hypertrophy and diastolic dysfunction, but none 
Fig. 1 Schematic representa-
tion of HFpEF pathophysiology. 
Comorbidities are associated with 
systemic changes and myocardial 
molecular dysfunction translat-
ing into structural changes that 
contribute to HFpEF pathophysi-
ology. IL-6 interleukin-6, TNF-α 
tumour necrosis factor alpha, NO 
nitric oxide, ROS reactive oxygen 
species, MMPs matrix metallo-
proteinases, TGF-β transforming 
growth factor beta.
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ing a prevalence of 55–86 % in HFpEF patients [4]. Thus, 
not surprisingly, many models of HFpEF have hitherto 
involved studies of increased afterload and LV concentric 
hypertrophy (i.e. transverse-aortic constriction or systemic 
arterial hypertension) [4].
Rodent animal models of HFpEF
Aortic banding and systemic hypertension
Hypertension represents a major risk factor for several heart 
diseases and an important contributor to HFpEF [4], show-
Table 1 Rodent animal models of heart failure with preserved ejection fraction
Ref. Model Type Species Systolic 
function
Diastolic function LV 
structure
Fibrosis Features
Active 
relaxation
Passive 
stiffness 
Aortic Banding and Systemic Hypertension models
6 Dahl Salt-Sensitive G R SBP Tau  LVEDP  CH  Hypertension, IR, 
dyslipidaemia
8 DOCA-Salt P/S R/M SBP E/E’  E/A  LVEDP  
Stiffness 
CH  Hypertension, endothe-
lial dysfunction, oxidative 
stress, inflammation
10 Hypertrophic 
agonists
P R/M MPI  
LVdP/
dtmax
E/A  IVRT   
E/E’  E’  
Tau 
LVEDP  CH  Hypertension
12 Aortic constriction S R/M S  EF  E/A  Tau  
VRT 
LVEDP  CH  Hypertension
Diabetes Mellitus and Obesity models
17 db/db mice G M EES  
MPI 
E/A  
LVEDV 
LVEDP  H  DM type 2, hyperlipidaemia, 
obesity, IR, hyperinsulinae-
mia, hyperglicaemia, EA 
18, 
19
ob/ob mice G M EES  
CO 
E/A  Stiffness  H  DM type 2, leptin defi-
ciency, obesity, hyperglicae-
mia, hyperinsulinaemia, IR, 
Apoptosis, EA 
21 Obese Zucker rat G R S  IVRT  Stiffness  H  Obesity, hyperphagia
22 ZDF G R Intact E/A  Stiffness H  Obesity, hyperinsulinae-
mia, hyperglycaemia, 
hyperleptinaemia
24 OLETF G R S  DT  E/A  Stiffness  H  Hypertension, DM type 2
Cardiometabolic syndrome models
25 Dahl/SS/Obese G R ND E/A  Tau  LVEDP  H  Obesity, hypertension, 
dyslipidaemia, IR, DM 
type 2, oxidative stress, 
inflammation
26, 
27
ZSF1 obese G R Preserved Tau  E/E’  
Restrictive LV 
inflow signal
LVEDP  
Chamber and 
myocardial 
stiffness 
CH  Obesity, DM type 2, IR, 
hyperinsulinaemia, hyperti-
glycedaemia, hypercholes-
terolaemia, hypertension
Ageing models
29 FVB/N mice G M  E/A  Time to peak 
diastolic 
filling
CH  Age-dependent diastolic 
dysfunction in male mice
28 SAMP8 G M = E/A  E’  
E’/A’ 
LVEDP  
Chamber and 
myocardial 
stiffness 
  –
30, 
31
Fischer 344 G R EF  IVRT  E’  Stiffness  H  Female display more 
differences
ND Not determined, LVdP/dtmax Maximum rate of rise of left ventricular pressure, EES End-systolic elastance, EA arterial elastance, Tau time 
constant of relaxation, LVEDP LV end-diastolic pressure, DM diabetes mellitus, S peak systolic velocity, E/A ratio between early (E) and late (A) 
diastolic transmitral filling velocities, SBP systolic blood pressure, DT deceleration time, E’ early diastolic tissue Doppler mitral annulus velocity, 
IVRT isovolumetric relaxation time, G genetic, S surgical, P pharmacological, MPI myocardial performance index, IR insulin resistance, CO 
cardiac output, EF ejection fraction, R rat, M mouse, EF ejection fraction, CO cardiac output, H hypertrophy, CH concentric hypertrophy
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phy. Angiotensin II-treated rodents show evidence of hyper-
tension, increased LV hypertrophy, fibrosis and expression 
of natriuretic peptides, which result in diastolic dysfunc-
tion confirmed by increase/worsening in LV isovolumetric 
relaxation time (IVRT), myocardial performance index, τ, 
LVEDP, E/E’ along with decreased E/A, without changes in 
LV dimensions, mass, or ejection fraction [10]. In the same 
way, the use of isoprenaline displayed cardiac hypertrophy, 
myocardial fibrosis and decreased ventricular relaxation [11]. 
Notwithstanding, blockers of the renin-angiotensin-aldoste-
rone system or β-adrenergic receptors have not demonstrated 
appreciable benefit in patients with HFpEF.
Transverse-aortic constriction is a well-established sur-
gical technique for inducing LV chronic pressure overload 
and hypertrophy in rodents. Moderate transverse-aortic 
constriction imposed at an early age triggers concentric 
LV hypertrophy with compensated chamber performance, 
markedly with prominent diastolic filling abnormalities. 
Transmitral flow profile showed a ‘restrictive’ filling pattern 
with increased early (E-wave) and decreased late (A-wave) 
diastolic transmitral filling velocities, augmented E/E’ and 
left atrial diameter, more rapid deceleration of the early fill-
ing wave as well as a shortened IVRT. These abnormalities 
became progressively more exaggerated at 12 and 18 weeks 
[12], thus representing a good model for studying HFpEF. 
The transition from compensated hypertrophy to early fail-
ure (HFrEF) is heralded by LV dilation, impairment of sys-
tolic function and progression of the abnormal filling [12].
A major limitation of using aortic-banded or hyperten-
sive models is that the majority of patients with HFpEF con-
tinue to have heart failure symptoms even when the blood 
pressure is controlled. Conversely, less than 50 % of HFpEF 
patients have LV hypertrophy and often show no evidence 
of LV dilatation, thus making the value of the current pre-
clinical model questionable [13].
Diabetes mellitus
Approximately one-third of HFpEF patients have type 
2 DM and cardiovascular disease is the leading cause of 
morbidity and mortality in diabetic patients. Interestingly, 
diastolic dysfunction represents an early cardiac manifesta-
tion of the deleterious effects of DM, since young diabetic 
individuals predominantly display diastolic abnormalities, 
whereas HFrEF rarely develops before middle age in obese 
diabetic individuals [14]. Insulin resistance, type 2 DM and 
hyperinsulinaemia exert a number of pleiotropic effects 
on the myocardium, including stimulation of hypertrophy, 
increased oxidative stress and proinflammatory/profibrotic 
effects, which can induce deleterious changes in cardiomyo-
cyte function as well as in the extracellular matrix [15].
Many models of type 2 DM recapitulate the features 
of HFpEF patients, including leptin-deficient ob/ob mice 
The Dahl salt-sensitive (SS) rat was selectively bred 
from Sprague-Dawley presenting the highest values of 
blood pressure. Dahl/SS is characterised by hypersensi-
tivity to sodium intake and represents the most published 
HFpEF animal model [6]. When fed with a high-salt diet 
(8 % NaCl) from the age of 7 weeks, Dahl/SS rats develop 
renal failure, fast-developing hypertension (> 175 mmHg) 
and LV hypertrophy, falling into HFpEF between 12 and 19 
weeks of age [6]. At week 12, Dahl/SS rats develop diastolic 
dysfunction such as increased chamber stiffness (left and 
upward shift of end-diastolic pressure-volume relationship 
(EDPVR) and decrease of end-diastolic volume). Between 
16 and 20 weeks, Dahl/SS hearts enlarge so that end-dia-
stolic volumes and EDPVRs become similar to the respec-
tive age-matched controls. Concomitantly, overall pump 
function curves move towards control, and ejection fraction 
declines, thus, progressing towards HFrEF. Despite normal 
or enhanced overall pump function at a certain time-point, 
LV end-diastolic pressure (LVEDP) and wet lung weight 
increases, indicating the development of heart failure. Cau-
tion should be taken as some authors report HFrEF rather 
than HFpEF in Dahl/SS. It appears that subtle differences in 
the experimental design, such as the specific genetic back-
ground of the animals as well as environmental conditions, 
including diet, may importantly impact the cardiovascular 
phenotype of Dahl/SS.
The deoxycorticosterone acetate (DOCA) salt-induced 
rat model represents a pharmacologically induced model 
of hypertension. DOCA is administered by intraperito-
neal or subcutaneous injection at 7 weeks of age, 1 week 
after a unilateral nephrectomy. This combination results in 
hypertension, renal hypertrophy, nephrosclerosis, cardiac 
hypertrophy and perivascular fibrosis within 4–5 weeks of 
chronic DOCA treatment [7]. It is used in rats and mice, and 
isotonic saline is the sole drinking fluid, which accelerates 
and aggravates hypertension progression [8]. The DOCA-
salt hypertensive rat develops myocardial inflammation, 
oxidative stress, fibrosis and diastolic dysfunction. Diastolic 
dysfunction was confirmed by impaired relaxation (higher 
E/E’ and time constant of isovolumetric relaxation - τ) and 
increased stiffness (elevated EDPVR slope) compared to 
control subjects [8] and this seems to be related with the 
impact of oxidative stress on myofilamentary proteins [8]. 
Subsequently, a related model was developed, consisting 
of exposure to 2 weeks of transverse-aortic constriction 
prior to DOCA administration, demonstrating normal LV 
systolic pressure and fractional shortening but more hyper-
trophy, fibrosis and diastolic dysfunction (higher LVEDP 
and EDPVR) with increased lung weight, consistent with 
HFpEF [9].
Chronic stimulation with pro-hypertrophic agents, such 
as angiotensin II and isoprenaline, has been used as a model 
of systolic and diastolic dysfunction as well as LV hypertro-
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diographic evidence of diastolic dysfunction from 20 weeks 
of age as observed by deceleration time of the E-wave and 
decreased E/A [25].
Cardiometabolic syndrome
Dahl/SS/obese rats, derived from Dahl/SS and Zucker 
crossing, have been recently established as a new model of 
metabolic syndrome. At 15 weeks of age, female Dahl/SS/
obese rats present with LV diastolic dysfunction, marked LV 
hypertrophy and fibrosis, associated with increased cardiac 
oxidative stress and inflammation [26].
A recently discovered HFpEF model is the obese ZSF1 
rat. The ZSF1 rat was generated by crossing non-hyper-
tensive lean female Zucker diabetic fatty rats (ZDF, +/fa) 
with lean spontaneously hypertensive heart failure prone 
male rats (SHHF/Mcc, +/facp), sharing a common genetic 
background with Wistar Kyoto rats [27]. Both lean and 
obese ZSF1 animals inherit a hypertensive gene from the 
spontaneously hypertensive rat strain and show elevated 
blood pressure [27]. The 20-week-old obese ZSF1 rat rep-
resents a robust model of metabolic syndrome since it dis-
plays hypertension, obesity, type 2 DM, insulin resistance, 
hyperinsulinaemia, hypertriglyceridaemia, hypercholester-
olaemia and heart failure. Considering such features, this 
cardiometabolic risk model develops diastolic dysfunction 
such as prolonged τ, an upwards shift of EDPVR and ele-
vated arterial elastance. Along with higher resting LVEDP, 
obese ZSF1 rats show reduced effort tolerance and VO2max, 
showing, for the first time in an animal model, an important 
corresponding feature of HFpEF human diagnosis - exer-
cise intolerance. In parallel, there is LV hypertrophy and left 
atrial dilation (Fig. 2), without signs of renal failure at 20 
weeks of age [28]. In male obese ZSF1 rats, the increased 
myocardial stiffness appears mostly due to myofilament 
changes, without significant interstitial fibrosis [28]. A sub-
group of ZSF1 obese rats subjected to a Western high-fat 
diet for 10 weeks showed no further aggravation of HFpEF 
phenotype [28].
Ageing
The prevalence of HFpEF in the community increases with 
advancing age and is higher in women. Indeed, the reported 
age- and sex-specific prevalence for individuals 80 years 
and older is about 4–6 % in men and 8–10 % in women [21]. 
Thus, ageing models are important to understand the patho-
physiology of age-related diastolic dysfunction.
The spontaneous senescence-prone (SAMP8) mouse 
offers a good model of cardiac dysfunction associated with 
ageing. At 6 months of age, this animal model displayed a 
significant reduction of E/A ratio, E’ and E’/A’ along with 
increased EDPVR, fibrosis and TGF-β expression when 
and the leptin receptor-deficient db/db mice, whose altered 
leptin homeostasis leads to obesity due to hyperphagia, 
hyperglycaemia, hyperinsulinaemia, insulin resistance and 
diabetic complications at different time points [16].
Db/db mice develop cardiac hypertrophy as evidenced 
by increased LV mass and wall thickness at 9 weeks of age, 
which is associated with a smaller LV end-diastolic volume. 
The progression of diabetic cardiomyopathy is accompa-
nied by increased production of reactive oxygen species 
and interstitial fibrosis [17]. Five-month-old mice display 
haemodynamic alterations such as elevated LVEDP and 
EDPVR, reduced dP/dtmin, and prolonged relaxation. At this 
age, transthoracic echocardiography confirmed preserved 
systolic function with elevated IVRT and reduced E/A, 
clearly indicating diastolic dysfunction [17]. The administra-
tion of angiotensin II for 4 weeks in db/db mice induced the 
expression of markers of hypertrophy and fibrosis but did not 
impact greatly on cardiac structure or lead to HFpEF [18].
Ob/ob mouse is an obesity and diabetic animal model 
that shows evidence of diastolic dysfunction possibly due 
to cardiac lipid accumulation [19]. Ob/ob mice develop 
myocardial hypertrophy and triglyceride accumulation, 
which parallels LV diastolic dysfunction as confirmed by 
decreased E/A [19]. Progressively, this animal model devel-
ops diabetic cardiomyopathy with impaired contractility 
and relaxation [20].
Obesity
The increase in global incidence of obesity predicts a con-
tinuous rise of the burden of cardiovascular diseases. This 
is particularly true for HFpEF, as obesity has a preva-
lence of 41–46 %, is associated with an increased risk of 
hypertension, dyslipidaemia and diabetes and thus repre-
sents an independent risk factor for its development [21]. 
Many available models of obesity are derived from selec-
tive crossing between rats comprising one out of the two 
most significant mutations in leptin receptor (i.e. fa and cp). 
These models are usually associated with other risk factors, 
including hypertension and/or diabetes, with some of them 
developing diastolic dysfunction or HFpEF.
Zucker rats were originally bred to be a genetic model 
of obesity and hypertension. The obese Zucker rat demon-
strates a consistent increase in LV mass and early diastolic 
dysfunction with prolonged IVRT [22]. In contrast, the 
obese diabetic Zucker (ZDF) rat does not develop increased 
LV mass even though mild hypertension is present and dia-
stolic dysfunction is evident [23].
The Otsuka Long-Evans Tokushima Fatty (OLETF) rat 
was derived by selecting spontaneously diabetic rats dis-
playing polyuria, polydipsia and obesity from an outbred 
colony of Long-Evans rats [24]. The OLETF rat is used as 
a model of diabetic cardiomyopathy and displays echocar-
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Aortic banding
A considerable number of aortic banding studies have been 
performed and many have yielded significant insights into 
the pathophysiology of HFpEF, well before the actual term 
was even established. The most consistent finding from 
pressure-overload studies is the principally concentric 
type of LV hypertrophy that is produced and which is often 
observed in HFpEF. In addition, these studies [33–35] have 
revealed the presence of impaired myocardial blood flow 
reserve, particularly during exercise, impaired endothe-
lial function of large coronary artery, enhanced apoptosis, 
abnormalities in bioenergetics and metabolism, exhausted 
myocardial perfusion and exaggerated oxygen consump-
tion during exercise, all of which are likely contributors 
to diastolic dysfunction in this model [36]. Nonetheless, 
cardiac dysfunction is often variable, as in patients, and 
not always even evident as assessed in vivo although 
abnormalities at the myocyte level are still present [37]. 
Furthermore, these earlier studies concentrated mostly on 
functional aspects and, apart from increased fibrosis [38], 
histological information from these studies remains lim-
ited. Increased LV fibrosis was documented by Yarborough 
et al. who also reported increased LV diastolic stiffness 
in a model of HFpEF induced by progressive aortic cuff 
inflation [39]. In their study, increased LV fibrosis was due 
to enhanced collagen stability but not its expression, and 
collagen content correlated with myocardial stiffness [39]. 
compared to the control group (SAMR1). No differences in 
systolic function or mean arterial pressure were reported in 
SAMP8 mice [29].
FVB/N mice represent a robust inbred strain and males 
display diastolic dysfunction at 12 months, with an E/A < 1 
while, in females, this phenotype is not observed [30]. 
In contrast, Fischer 344 ageing rats showed more promi-
nent LV hypertrophy and diastolic dysfunction in females 
compared to males, as assessed by increased IVRT and 
decreased septal E’. Instead, males displayed fibrosis and 
systolic dysfunction [31]. Other studies aiming to evaluate 
age-related cardiac changes using male Fischer 344/Brown 
Norway F1 rats revealed a decline in cardiac function and 
LV structural changes, compatible with the phenotype of 
HFpEF [32].
Large animal models of HFpEF
Although the large number of rodent models has impor-
tantly contributed to our understanding of the underlying 
causes and mechanisms of LV diastolic dysfunction, rodents 
have inherent limitations due to their size, cardiac structure 
and function compared to larger mammalian species, in 
particular the human heart. Therefore, experimental mod-
els of human heart failure have also been recapitulated in 
large animal models, which have been particularly useful in 
elucidating several important pathophysiological aspects of 
diastolic dysfunction and HFpEF (Table 2; [5]).
KEY MESSAGE  &DUGLRPHWDEROLFV\QGURPHPRGHO±=6)2EHVH
Fig. 2 Representative pressure-volume (P-V) loops and echocardiog-
raphy tracings from Wistar-Kyoto (normotensive control group of 
obese ZSF1 rats), lean ZSF1 (hypertensive lean control group of obese 
ZSF1 rats, ZSF1 Ln) and obese ZSF1 (ZSF1 Ob). A late diastolic trans-
mitral filling velocities, A’ late diastolic tissue Doppler mitral annulus 
velocity, E early filling transmitral Doppler velocity, E’ early diastolic 
tissue Doppler mitral annulus velocity, S’ peak systolic tissue Doppler 
mitral annular velocity
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ity were all comparable with control levels [40]. In con-
trast, humoral activation (renin activity, aldosterone, brain 
natriuretic peptide and adrenomedullin) was increased in 
bilateral renal wrapping performed by Maniu and col-
leagues [41]. To our knowledge, the first large animal 
study designed to specifically address HFpEF was per-
formed by Munagala et al. [42], who showed that bilateral 
renal wrapping-induced hypertension resulted in increased 
arterial stiffness, associated with an increased LV mass 
and fibrosis in old dogs, although LV volume and also LV 
diastolic stiffness were similar to healthy controls [42]. 
These authors also reported enhanced end-systolic elas-
tance in this model of HFpEF. Renal wrapping in dogs has 
also been studied by Hayashida and colleagues, for testing 
of novel pharmacological treatments for HFpEF [43], and 
this model continues to be used. Renal wrapping was also 
applied in an early study in nonhuman primates by Abra-
hams and colleagues, who observed a progressive increase 
in LV collagen content, with cardiomyocytes ultimately 
becoming encased by collagen after 80 weeks of follow-
up [44].
Aortic banding-induced HFpEF was recently investigated 
by Emter and colleagues [33, 38]. In support of earlier 
findings, these authors documented enhanced fibrosis in 
the left ventricle of aortic banded swine, but also showed 
that exercise training is a promising treatment in HFpEF, 
as it promotes compliant extracellular matrix fibrotic 
components and preserves extracellular matrix regula-
tory mechanisms. In addition, exercise training preserved 
myocardial oxygen balance, and promoted physiological 
molecular hypertrophic signalling cardiac phenotype [33, 
38]. This is important, as no proven pharmacological treat-
ments have yet been reported for HFpEF.
Renal wrapping
Renal wrapping-induced hypertension has been exten-
sively used in dogs. Hart and colleagues reported that this 
model increased LV fibrosis and mass, which was accom-
panied by elevations in LVEDP 12 weeks after renal wrap-
ping [40]. In their study, LV end-diastolic volume, ejection 
fraction, stroke volume, cardiac output and neurohumoral 
activity including circulating angiotensin II, endothelin 
and catecholamine levels as well as plasma renin activ-
Table 2 Large animal models of heart failure with preserved ejection fraction
Ref. Species Disease model Systolic function Diastolic function LV structure Fibrosis Arterial 
stiffness
Coronary 
vascular 
dysfunction
Active relaxation Passive stiffness
41 MC Renal wrap ND ND ND ND Progressive 
 over 80 
wk
ND ND
40 D Renal wrap LVdP/dtmax Tau  Chamber and 
myocardial 
stiffness 
CH ND ND MBF 
40 D Renal wrap EES  Tau  LVEDP  
Stiffness ND
CH ND ND ND
37 D Renal wrap EES  Tau  LVEDP  
Stiffness 
CH  EA  ND
39 D Renal wrap 
in young + old 
animals
EES  Tau   CH  EA  ND
39 D Renal wrap in 
old animals
EES   EES  Fpass  –  EA  ND
36 Sn Aortic banding Contractile 
reserve 
Tau  ND H  ND ET-1 
responses  
Ca2+ signal-
ling 
35 Sn Gradual aortic 
cuff inflation
 Tau  Stiffness  H  ND ND
42 MR Spontaneous 
DM type 2
S  or 
somewhat 
Variable, E’ 
and E/A  or 
pseudonormal
ND A trend to 
thinner walls 
in diabetes
ND ND ND
ND Not determined, LVdP/dtmax maximum rate of rise of left ventricular pressure, EES end-systolic elastance, Tau time constant of relaxation, 
MBF myocardial blood flow, LVEDP LV end-diastolic pressure, EA arterial elastance, FPASS cardiomyocyte passive force, ET-1 endothelin-1, DM 
diabetes mellitus, S peak systolic velocity, E’ early diastolic tissue Doppler mitral annulus velocity, E/A ratio between early (E) and late (A) diastolic 
transmitral filling velocities, D dog, Sn swine, MR macaque rhesus, MC macaque cynomolgus, CH concentric hypertrophy, H hypertrophy
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ric relaxation times and mitral valve velocities, especially 
when non-invasive techniques, such as echocardiography, 
are used to determine cardiac function. In contrast, large 
animal heart failure pathophysiology is more similar to that 
of humans, but ethical concerns and difficulty in achieving 
trans-genesis in large animals still limit research. Not sur-
prisingly, heart failure models were originally developed in 
rodents because of the numerous advantages inherent to a 
small animal model, including lower housing and mainte-
nance costs, thus allowing a larger number of animals to 
be included in a study and improving its statistical power. 
Moreover, recent technological advances in echocardiog-
raphy, MRI, and micromanometer conductance catheters 
have greatly facilitated assessment of cardiac function in 
rodents, removing a significant barrier to their use in heart 
failure research [49]. Among rodents, the major advantage 
of mice compared to rats is the fact that pharmacological 
studies become less expensive as the drug is usually admin-
istered proportionately to body weight. Mice major limita-
tion is the amount of cardiac mass to perform post-mortem 
analysis. With regard to diastolic dysfunction, it should be 
emphasised that rodent models generally progress to HFrEF 
within a variable amount of time, which means that, in those 
animals, HFpEF is merely a temporary step in the develop-
ment of HFrEF. In contrast, several human pathologies are 
characterised by stable and isolated HFpEF, which does not 
necessarily progress towards HFrEF.
A general limitation of most animal models of heart 
failure is the sudden onset of heart failure due to a surgi-
cal or drug intervention, whereas human heart failure gen-
erally develops over a period of several years. Moreover, 
in humans, HFpEF is a condition typically associated with 
ageing and the diastolic dysfunction/HFpEF animal mod-
els are typically relatively young. Finally, human HFpEF is 
often associated with comorbidities, including atherosclero-
sis, hypertension, diabetes or obesity, while development of 
atherosclerosis is rather rare in most rodent strains, at least 
without genetic modifications [50].
Conclusion
Several animal models of HFpEF have been developed that 
recapitulate some, but not necessarily all, of the character-
istics described in HFpEF patients. This significantly limits 
their usefulness in developing novel therapeutic strategies 
for HFpEF. Researchers need to decide what risk factor or 
combination of risk factors leading to this multifactorial dis-
ease should be included in their protocol design according 
to the purpose of study. The choice of appropriate models is 
thus essential and will lead to better understanding and find-
ing of new knowledge in this increasingly prevalent disease.
Obesity, metabolic syndrome and diabetes mellitus animal 
models
In comparison with studies in rodent models (Table 1), obe-
sity or metabolic syndrome (such as high fat diet alone or 
in combination with experimental diabetes) induced HFpEF 
has been sparsely studied in large animal models. Diastolic 
dysfunction, albeit in a variable degree, was however docu-
mented recently in type 2 DM rhesus monkeys (Table 2), 
although LV histology was performed in only one diseased 
animal [45]. Furthermore, several large animal models 
with features of metabolic syndrome have demonstrated 
alterations in coronary vascular function and structure. For 
instance, Trask et al. described in obese Ossabaw swine with 
metabolic syndrome an hypertrophic inward remodelling 
of coronary resistance microvessels along with coronary 
capillary rarefaction, which was associated with a decrease 
in coronary flow and myocardial ischaemia [46]. In a pre-
atherosclerotic diabetes mellitus porcine model with type 
2 characteristics small coronary arteries displayed reduced 
nitric oxide bioavailability and loss of endothelin-1 response 
[47]. Unfortunately, cardiac function was not investigated, 
and thus future studies are required to assess the impact of 
these coronary vascular abnormalities on cardiac function.
Ageing models
With advancing age, the cardiovascular system is known to 
stiffen, while the prevalence of HFpEF increases. Hence, 
ageing dogs have been used to investigate the effect of age 
on features of HFpEF. Ageing alone did not have a major 
influence on LV structure and function in the study by 
Munagala et al., but the combination of old age and renal 
wrapping resulted in impairments in diastolic function 
although myocardial fibrosis was similar to control levels 
[42], suggesting that hypertension rather than age was the 
causal factor [42]. Conversely, a decrease in LV distensibil-
ity was observed in aged compared to young dogs, which 
was accompanied by an increase in LVEDP and a decrease 
in LV end-diastolic volume [48]. As ejection fraction and 
LV mass were not affected, this model recapitulates several 
aspects of HFpEF and may prove useful in future studies.
Discussion
The use of animal models has proven to be an extremely 
valuable tool in understanding the pathophysiology of com-
plex cardiovascular diseases such as HFpEF, even consider-
ing that the experimental results are not readily transferable 
to human patients. In this regard, rodents present distinct 
cardiac features, such as its structure and higher heart 
rates, which often preclude obtaining reliable isovolumet-
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